Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
最近 90 天内有 6 个信号。
该公司进入各个市场的顺序 — 从最早到最新
甘李药业与JW制药达成合作
甘李药业与JW制药达成合作
注册以查看完整信号动态
Gan & Lee Pharmaceuticals 的国际扩张与竞争对手的对比情况
Gan & Lee Pharmaceuticals你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Gan & Lee Pharmaceuticals你 | 2 | 1 | -100% | 6 | 49 |
Regulatory Affairs VP
查看职位Bandar Banang Jaya, Johore, Malaysia · 9个月前
Senior Manager, Regulatory Affairs - EU
查看职位Germany · 11个月前
principal investigator of Biopharmaceuticals
查看职位Beijing, China · 去年
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
FDA批准甘李药业的GZR18进行二期临床试验，与礼来公司的Tirzepatide进行头对头比较，用于肥胖治疗。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Gan & Lee Pharmaceuticals 的业务、市场和增长信号的快速解答。
